Tag: nasdaq:alny

November 24, 2019

5 Top NASDAQ Biotech and Pharma Stocks: Fulcrum Climbs 73 Percent

Which biotech and pharma stocks were on the rise last week? We list the top gainers and what may have...
November 20, 2019

Alnylam Gets FDA Nod for Rare Disease Drug

The FDA's approval of Alnylam's Gilvaari treatment is the first approval of its kind for acute hepatic porphyria.
August 13, 2019

Ironwood and Alnylam Enter US GI Disease Education and Promotional Agreement

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ironwood Pharmaceuticals (NASDAQ:IRWD) has announced a US GI disease education and promotional agreement for Alnylam’s givosiran...
January 21, 2019

Alnylam Pharmaceuticals and Medison Pharma Partner to Commercialize RNAi Therapeutics in Israel

Alnylam Pharmaceuticals (Nasdaq:ALNY), the leading RNAi therapeutics company, and Medison Pharma, Israel’s leading commercial partner for innovative pharmaceuticals, announced today an...
January 17, 2019

How Will the FDA Shutdown Affect the Biotech Industry?

No information has been released on how the FDA will manage the possible influx of drug applications once the shutdown...
October 15, 2018

Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application

Alnylam Pharmaceuticals (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that in consultation with the U.S. Food and Drug Administration (FDA),...
August 21, 2018

Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias

Alnylam Pharmaceuticals (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that it has achieved full patient accrual in its ENVISION Phase...